Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.057
Filtrar
1.
BMC Infect Dis ; 20(1): 361, 2020 May 20.
Artículo en Inglés | MEDLINE | ID: mdl-32434466

RESUMEN

BACKGROUND: Neisseria meningitidis has rarely been described as an agent of necrotic soft tissue infection. CASE PRESENTATION: We report a case of a septic shock with necrotizing cellulitis due to Neisseria meningitidis serogroup W, treated by urgent extensive surgical debridement followed by skin grafts. The invasive meningococcal disease occurred together with a complement deficiency, possibly acquired after bypass surgery that took place 1 year before. CONCLUSIONS: Necrotic tissue infections should be considered part of the invasive meningococcal diseases spectrum and should prompt clinicians to look for complement deficiencies. Gastric bypass surgery associated malnutrition may be implicated but further verification is needed.


Asunto(s)
Celulitis (Flemón)/microbiología , Derivación Gástrica/efectos adversos , Infecciones Meningocócicas/complicaciones , Bacteriemia/microbiología , Bacteriemia/terapia , Celulitis (Flemón)/etiología , Celulitis (Flemón)/terapia , Proteínas del Sistema Complemento/deficiencia , Desbridamiento , Femenino , Humanos , Infecciones Meningocócicas/terapia , Persona de Mediana Edad , Neisseria meningitidis , Choque Séptico/etiología , Choque Séptico/terapia , Infecciones de los Tejidos Blandos/etiología , Infecciones de los Tejidos Blandos/microbiología , Infecciones de los Tejidos Blandos/terapia
2.
Microbes Infect ; 22(1): 19-30, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31473336

RESUMEN

The Gram-negative bacterium Klebsiella pneumoniae is an opportunistic pathogen, which can cause life-threatening infections such as sepsis. Worldwide, emerging multidrug resistant K. pneumoniae infections are challenging to treat, hence leading to increased mortality. Therefore, understanding the interactions between K. pneumoniae and the immune system is important to develop new treatment options. We characterized ten clinical K. pneumoniae isolates obtained from blood of bacteremia patients. The interaction of the isolates with human serum was investigated to elucidate how K. pneumoniae escapes the host immune system, and how complement activation by K. pneumoniae changed the capsule structure. All K. pneumoniae isolates activated the alternative complement pathway despite serum resistance of seven isolates. One serum sensitive isolate activated two or all three pathways, and this isolate was lysed and had numerous membrane attack complexes in the outer membrane. However, we also found deposition of complement components in the capsule of serum resistant isolates resulting in morphological capsule changes and capsule shedding. These bacteria did not lyse, and no membrane attack complex was observed despite deposition of C5b-9 within the capsule, indicating that the capsule of serum resistant K. pneumoniae isolates is a defense mechanism against complement-mediated lysis.


Asunto(s)
Cápsulas Bacterianas/inmunología , Proteínas del Sistema Complemento/inmunología , Infecciones por Klebsiella/microbiología , Klebsiella pneumoniae/inmunología , Bacteriemia/inmunología , Bacteriemia/microbiología , Cápsulas Bacterianas/metabolismo , Actividad Bactericida de la Sangre , Activación de Complemento , Complejo de Ataque a Membrana del Sistema Complemento/metabolismo , Proteínas del Sistema Complemento/deficiencia , Interacciones Huésped-Patógeno , Humanos , Infecciones por Klebsiella/inmunología , Klebsiella pneumoniae/aislamiento & purificación
3.
Front Immunol ; 10: 1936, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31440263

RESUMEN

The complement system is crucial for defense against pathogens and the removal of dying cells or immune complexes. Thus, clinical indications for possible complete complement deficiencies include, among others, recurrent mild or serious bacterial infections as well as autoimmune diseases (AID). The diagnostic approach includes functional activity measurements of the classical (CH50) and alternative pathway (AP50) and the determination of the C3 and C4 levels, followed by the quantitative analysis of individual components or regulators. When biochemical analysis reveals the causal abnormality of the complement deficiency (CD), molecular mechanisms remains frequently undetermined. Here, using direct sequencing analysis of the coding region we report the pathogenic variants spectrum that underlie the total or subtotal complement deficiency in 212 patients. We identified 107 different hemizygous, homozygous, or compound heterozygous pathogenic variants in 14 complement genes [C1Qß (n = 1), C1r (n = 3), C1s (n = 2), C2 (n = 12), C3 (n = 5), C5 (n = 12), C6 (n = 9), C7 (n = 17), C8 ß (n = 7), C9 (n = 3), CFH (n = 7), CFI (n = 18), CFP (n = 10), CFD (n = 2)]. Molecular analysis identified 17 recurrent pathogenic variants in 6 genes (C2, CFH, C5, C6, C7, and C8). More than half of the pathogenic variants identified in unrelated patients were also found in healthy controls from the same geographic area. Our study confirms the strong association of meningococcal infections with terminal pathway deficiency and highlights the risk of pneumococcal and auto-immune diseases in the classical and alternative pathways. Results from this large genetic investigation provide evidence of a restricted number of molecular mechanisms leading to complement deficiency and describe the clinical potential adverse events of anti-complement therapy.


Asunto(s)
Proteínas del Sistema Complemento/deficiencia , Proteínas del Sistema Complemento/genética , Enfermedades por Deficiencia de Complemento Hereditario/genética , Enfermedades por Deficiencia de Complemento Hereditario/inmunología , Adolescente , Adulto , Enfermedades Autoinmunes/genética , Enfermedades Autoinmunes/inmunología , Niño , Preescolar , Estudios de Cohortes , Activación de Complemento/genética , Activación de Complemento/inmunología , Proteínas del Sistema Complemento/inmunología , Femenino , Humanos , Masculino , Infecciones Meningocócicas/genética , Infecciones Meningocócicas/inmunología , Adulto Joven
4.
Arch. Health Sci. (Online) ; 26(1): 62-66, 28/08/2019.
Artículo en Portugués | LILACS | ID: biblio-1046127

RESUMEN

Introdução: O sistema complemento é composto por diversas proteínas plasmáticas e é um importante mecanismo de defesa da imunidade inata e adquirida, que exerce funções homeostáticas e fisiológicas, como a remoção de células apoptóticas e complexos imunes. A deficiência neste mecanismo pode ser hereditária ou adquirida, e leva ao aumento da susceptibilidade a doenças infecciosas e não infecciosas, raras e fatais. Objetivo: Descrever as principais causas e consequências da deficiência do sistema complemento e relacioná-las com múltiplas patologias. Material e Métodos: Trata-se de uma revisão bibliográfica narrativa, tendo como base de dados, artigos publicados no Scientific Electronic Library Online (SciELO), National Library of Medicine (PubMed), Medical Literature Analysis and retrieval System Online (MEDLINE), nos últimos 5 anos. Resultados: A associação do complemento e doenças foram observadas em situações de deficiência do sistema complemento, anormalidades na regulação e nas inflamações. Mutações genéticas ou aumento do consumo do complemento levam à ativação imprópria ou excessiva do complemento, podendo conduzir a consequências lesivas e ao desenvolvimento de diversas doenças, como, lúpus eritematoso sistêmico, síndrome urêmica hemolítica atípica, glomerulopatia C3, hemoglobinúria paroxística noturna, glomerulonefrite pós-infecciosas, artrite reumatoide, dentre outras. Conclusão: É evidente a participação do sistema complemento na patogênese e patogenia de diversas doenças. O investimento em pesquisas, que visem ampliar o entendimento do papel do mecanismo do sistema complemento, pode contribuir para o desenvolvimento de intervenções terapêuticas paliativas e ou de cura de diversas doenças, com a consequente melhoria da qualidade de vida dos indivíduos acometidos.


Introduction: The complement system is composed of several plasma proteins and is an important defense mechanism of innate and acquired immunity, which exerts homeostatic and physiological functions, such as the removal of apoptotic cells and immune complexes. Deficiency in this mechanism may be hereditary or acquired, and leads to increased susceptibility to infectious and non-infectious, rare and fatal diseases. Objective: To describe the main causes and consequences of the deficiency of the complement system and to relate them to multiple pathologies. Material and Methods: This is a bibliographical narrative review, based on data published in SciELO (Scientific Electronic Library Online), PubMed (National Library of Medicine), MEDLINE (Medical Literature Analysis and retrieval System Online), last five years. Results:The associations of complement and diseases were observed in situations of deficiency of the complement system, abnormalities in regulation and inflammation. Genetic mutations lead to inappropriate or excessive activation of the complement, as well as increased the consumption of the complement. This can lead to harmful consequences and the development of several diseases, such as systemic lupus erythematosus, atypical hemolytic uremic syndrome, C3 glomerulopathy, nocturnal paroxysmal hemoglobinuria, postpartum glomerulonephritis, infectious diseases, rheumatoid arthritis, among others. Conclusion: The participation of the complement system in the pathogenesis and pathogenesis of several diseases is evident. Investing in research, aimed at broadening the understanding of the role of the complement system mechanism, may contribute to the development of palliative therapeutic interventions and or cure of various diseases, with the consequent improvement in the quality of life of affected individuals.


Asunto(s)
Proteínas del Sistema Complemento/deficiencia , Enfermedad/etiología , Proteínas del Sistema Complemento/genética , Activación de Complemento
5.
BMC Infect Dis ; 19(1): 522, 2019 Jun 14.
Artículo en Inglés | MEDLINE | ID: mdl-31200658

RESUMEN

BACKGROUND: To describe patients with inherited and acquired complement deficiency who developed invasive meningococcal disease (IMD) in England over the last decade. METHODS: Public Health England conducts enhanced surveillance of IMD in England. We retrospectively identified patients with complement deficiency who developed IMD in England during 2008-2017 and retrieved information on their clinical presentation, vaccination status, medication history, recurrence of infection and outcomes, as well as characteristics of the infecting meningococcal strain. RESULTS: A total of 16 patients with 20 IMD episodes were identified, including four with two episodes. Six patients had inherited complement deficiencies, two had immune-mediated conditions associated with complement deficiency (glomerulonephritis and vasculitis), and eight others were on Eculizumab therapy, five for paroxysmal nocturnal haemoglobinuria and three for atypical haemolytic uraemic syndrome. Cultures were available for 7 of 11 episodes among those with inherited complement deficiencies/immune-mediated conditions and the predominant capsular group was Y (7/11), followed by B (3/11) and non-groupable (1/11) strains. Among patients receiving Eculizumab therapy, 3 of the 9 episodes were due to group B (3/9), three others were NG but genotypically group B, and one case each of groups E, W and Y. CONCLUSIONS: In England, complement deficiency is rare among IMD cases and includes inherited disorders of the late complement pathway, immune-mediated disorders associated with low complement levels and patients on Eculizumab therapy. IMD due to capsular group Y predominates in patient with inherited complement deficiency, whilst those on Eculizumab therapy develop IMD due to more diverse capsular groups including non-encapsulated strains.


Asunto(s)
Proteínas del Sistema Complemento/deficiencia , Síndromes de Inmunodeficiencia/complicaciones , Infecciones Meningocócicas/complicaciones , Infecciones Meningocócicas/microbiología , Neisseria meningitidis/genética , Adolescente , Adulto , Anticuerpos Monoclonales Humanizados/efectos adversos , Niño , Preescolar , Inglaterra/epidemiología , Genotipo , Humanos , Síndromes de Inmunodeficiencia/etiología , Infecciones Meningocócicas/epidemiología , Programas Nacionales de Salud/estadística & datos numéricos , Polisacáridos Bacterianos/genética , Estudios Retrospectivos , Adulto Joven
6.
Clin Rheumatol ; 38(6): 1691-1697, 2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-30980192

RESUMEN

Hypocomplementemic urticarial vasculitis syndrome (HUVS) is a rare type III hypersensitivity disorder characterized by urticarial vasculitis and prolonged hypocomplementemia. Individuals with HUVS may also have joint involvement, pulmonary manifestations, ocular disease, kidney inflammation, or any other form of organ involvement. Hypocomplementemia, the presence of C1q antibody in the serum, and urticarial vasculitis are the keys to the diagnosis of HUVS. It has been reported to accompany certain infections such as hepatitis B, hepatitis C, infectious mononucleosis, and coxsackie group A. However, it has never been reported to be linked to histoplasmosis in the literature. To the best of our knowledge, we report the first case of HUVS presenting concurrently with pulmonary histoplasmosis.


Asunto(s)
Proteínas del Sistema Complemento/deficiencia , Histoplasmosis/diagnóstico , Enfermedades Pulmonares Fúngicas/diagnóstico , Urticaria/diagnóstico , Vasculitis/diagnóstico , Histoplasmosis/complicaciones , Humanos , Pulmón/patología , Enfermedades Pulmonares Fúngicas/complicaciones , Masculino , Persona de Mediana Edad , Síndrome , Tomografía Computarizada por Rayos X , Urticaria/complicaciones , Urticaria/patología , Vasculitis/complicaciones , Vasculitis/patología
8.
J Allergy Clin Immunol Pract ; 7(3): 819-823, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30677537

RESUMEN

Routine antibacterial prophylaxis is recommended before dental procedures in select patient populations. Currently, no guidelines are in place for routine prophylaxis before dental procedures in patients with primary immunodeficiency diseases. We review risk factors and provide recommendations on routine dental care and antibacterial prophylaxis in patients with primary immunodeficiency diseases.


Asunto(s)
Profilaxis Antibiótica , Atención Odontológica , Síndromes de Inmunodeficiencia/tratamiento farmacológico , Anticuerpos , Proteínas del Sistema Complemento/deficiencia , Humanos , Microbiota , Boca/microbiología , Neutrófilos
9.
Front Immunol ; 9: 2237, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30405598

RESUMEN

Complement system aberrations have been identified as pathophysiological mechanisms in a number of diseases and pathological conditions either directly or indirectly. Examples of such conditions include infections, inflammation, autoimmune disease, as well as allogeneic and xenogenic transplantation. Both prospective and retrospective studies have demonstrated significant complement-related differences between patient groups and controls. However, due to the low degree of specificity and sensitivity of some of the assays used, it is not always possible to make predictions regarding the complement status of individual patients. Today, there are three main indications for determination of a patient's complement status: (1) complement deficiencies (acquired or inherited); (2) disorders with aberrant complement activation; and (3) C1 inhibitor deficiencies (acquired or inherited). An additional indication is to monitor patients on complement-regulating drugs, an indication which may be expected to increase in the near future since there is now a number of such drugs either under development, already in clinical trials or in clinical use. Available techniques to study complement include quantification of: (1) individual components; (2) activation products, (3) function, and (4) autoantibodies to complement proteins. In this review, we summarize the appropriate indications, techniques, and interpretations of basic serological complement analyses, exemplified by a number of clinical disorders.


Asunto(s)
Angioedemas Hereditarios/inmunología , Biomarcadores/análisis , Activación de Complemento/inmunología , Proteínas del Sistema Complemento/inmunología , Síndromes de Inmunodeficiencia/inmunología , Angioedemas Hereditarios/diagnóstico , Autoanticuerpos/inmunología , Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/inmunología , Proteínas del Sistema Complemento/deficiencia , Humanos , Síndromes de Inmunodeficiencia/diagnóstico , Estudios Prospectivos , Estudios Retrospectivos
10.
Pediatrics ; 142(3)2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-30068713

RESUMEN

BACKGROUND: The capsular group B meningococcal vaccine (4CMenB) is recommended for children with complement deficiencies, asplenia, and splenic dysfunction; however, data on the immunogenicity of 4CMenB in these "at-risk" children are missing. METHODS: Participants aged 2 to 17 years in Italy, Spain, Poland, the United Kingdom, and Russia with complement deficiencies, asplenia, or splenic dysfunction received 2 doses of 4CMenB 2 months apart, as did healthy children in the control group. Exogenous and endogenous human complement serum bactericidal activity (SBA) was determined at baseline and 1 month after the second immunization against 4 test strains: H44/76 (assessing vaccine antigen factor H binding protein), 5/99 (Neisserial adhesion A), NZ98/254 (Porin A), and M10713 (Neisserial heparin binding antigen). RESULTS: Of 239 participants (mean age 10.3 years, 45% female), 40 children were complement deficient (9 eculizumab therapy, 4 terminal-chain deficiencies, 27 "other"), 112 children had asplenia or splenic dysfunction (8 congenital asplenia, 8 functional asplenia, 96 splenectomy), and 87 children were in the control group. After immunization, the proportions of complement-deficient participants with exogenous complement SBA titers ≥1:5 were 87% (H44/76), 95% (5/99), 68% (NZ98/254), and 73% (M10713), compared with 97%, 100%, 86%, and 94%, respectively, for asplenic children and 98%, 99%, 83%, and 99% for children in the control group. When testing with endogenous complement, strain-specific bactericidal activity was evident in only 1 eculizumab-treated participant and 1 terminal chain complement-deficient participant. CONCLUSIONS: 4CMenB administration is similarly immunogenic in healthy children and those with asplenia or splenic dysfunction. The significance of the trend to lower responses of SBA titers in complement-deficient children (especially those with terminal chain complement deficiency or those on eculizumab therapy) must be determined by ongoing surveillance for vaccine failures.


Asunto(s)
Proteínas del Sistema Complemento/deficiencia , Inmunogenicidad Vacunal/fisiología , Infecciones Meningocócicas/prevención & control , Vacunas Meningococicas/uso terapéutico , Bazo/fisiología , Adolescente , Niño , Preescolar , Proteínas del Sistema Complemento/fisiología , Europa (Continente)/epidemiología , Femenino , Síndrome de Heterotaxia/tratamiento farmacológico , Síndrome de Heterotaxia/inmunología , Síndrome de Heterotaxia/microbiología , Humanos , Masculino , Infecciones Meningocócicas/epidemiología , Infecciones Meningocócicas/inmunología , Bazo/efectos de los fármacos , Bazo/microbiología
11.
Sci Rep ; 8(1): 10346, 2018 07 09.
Artículo en Inglés | MEDLINE | ID: mdl-29985461

RESUMEN

The purpose of this study was to study whether complement depletion induced by pretreatment with Cobra Venom Factor (CVF) could protect against lung ischemia reperfusion injury (LIRI) in a rat model and explore its molecular mechanisms. Adult Sprague-Dawley rats were randomly assigned to five groups (n = 6): Control group, Sham-operated group, I/R group, CVF group, I/R + CVF group. CVF (50 µg/kg) was injected through the tail vein 24 h before anesthesia. Lung ischemia reperfusion (I/R) was induced by clamping the left hilus pulmonis for 60 minutes followed by 4 hours of reperfusion. Measurement of complement activity, pathohistological lung injury score, inflammatory mediators, pulmonary permeability, pulmonary edema, integrity of tight junction and blood-air barrier were performed. The results showed that pretreatment with CVF significantly reduced complement activity in plasma and BALF. Evaluation in histomorphology showed that complement depletion induced by CVF significantly alleviated the damage of lung tissues and inhibited inflammatory response in lung tissues and BALF. Furthermore, CVF pretreatment had the function of ameliorating pulmonary permeability and preserving integrity of tight junctions in IR condition. In conclusion, our results indicated that complement depletion induced by CVF could inhibit I/R-induced inflammatory response and alleviate lung I/R injury. The mechanisms of its protective effects might be ameliorated blood-air barrier damage.


Asunto(s)
Barrera Alveolocapilar/efectos de los fármacos , Proteínas del Sistema Complemento/metabolismo , Venenos Elapídicos/farmacología , Sustancias Protectoras/farmacología , Daño por Reperfusión/patología , Animales , Barrera Alveolocapilar/metabolismo , Líquido del Lavado Bronquioalveolar/química , Proteínas del Sistema Complemento/deficiencia , Citocinas/metabolismo , Modelos Animales de Enfermedad , Venenos Elapídicos/uso terapéutico , Mediadores de Inflamación/metabolismo , Pulmón/efectos de los fármacos , Pulmón/metabolismo , Pulmón/patología , Permeabilidad/efectos de los fármacos , Sustancias Protectoras/uso terapéutico , Venas Pulmonares/metabolismo , Ratas , Ratas Sprague-Dawley , Daño por Reperfusión/prevención & control , Uniones Estrechas/metabolismo
13.
Arthritis Care Res (Hoboken) ; 70(2): 284-294, 2018 02.
Artículo en Inglés | MEDLINE | ID: mdl-28437595

RESUMEN

OBJECTIVE: To explore changes in the phenotypic features of Sjögren's syndrome (SS), and in SS status among participants in the Sjögren's International Collaborative Clinical Alliance (SICCA) registry over a 2-3-year interval. METHODS: All participants in the SICCA registry who were found to have any objective measures of salivary hypofunction, dry eye, focal lymphocytic sialadenitis in minor salivary gland biopsy, or anti-SSA/SSB antibodies were recalled over a window of 2 to 3 years after their baseline examinations to repeat all clinical examinations and specimen collections to determine whether there was any change in phenotypic features and in SS status. RESULTS: As of September 15, 2013, a total of 3,514 participants had enrolled in SICCA, and among 3,310 eligible, 771 presented for a followup visit. Among participants found to have SS using the 2012 American College of Rheumatology (ACR) classification criteria, 93% again met the criteria after 2 to 3 years, and this proportion was 89% when using the 2016 ACR/European League Against Rheumatism (EULAR) criteria. Among those who did not meet ACR or ACR/EULAR criteria at baseline, 9% and 8%, respectively, had progressed and met them at followup. Those with hypergammaglobulinemia and hypocomplementemia at study entry were, respectively, 4 and 6 times more likely to progress to SS by ACR criteria than those without these characteristics (95% confidence interval 1.5-10.1 and 1.8-20.4, respectively). CONCLUSION: While there was stability over a 2-3-year period of both individual phenotypic features of SS and of SS status, hypergammaglobulinemia and hypocomplementemia at study entry were predictive of progression to SS.


Asunto(s)
Síndrome de Sjögren/diagnóstico , Adulto , Argentina/epidemiología , Asia/epidemiología , Autoinmunidad , Biomarcadores/sangre , Proteínas del Sistema Complemento/deficiencia , Proteínas del Sistema Complemento/inmunología , Dinamarca/epidemiología , Progresión de la Enfermedad , Femenino , Humanos , Hipergammaglobulinemia/diagnóstico , Hipergammaglobulinemia/epidemiología , Hipergammaglobulinemia/inmunología , Masculino , Persona de Mediana Edad , Fenotipo , Valor Predictivo de las Pruebas , Pronóstico , Sistema de Registros , Factores de Riesgo , Síndrome de Sjögren/epidemiología , Síndrome de Sjögren/inmunología , Síndrome de Sjögren/fisiopatología , Factores de Tiempo , Estados Unidos/epidemiología
14.
Clin Microbiol Infect ; 23(8): 576.e1-576.e5, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28192236

RESUMEN

OBJECTIVES: Screening for primary immunodeficiencies (PIDs) in adults is recommended after two severe bacterial infections. We aimed to evaluate if screening should be performed after the first invasive infection in young adults. METHODS: Eligible patients were retrospectively identified using hospital discharge and bacteriology databases in three centres during a 3-year period. Eighteen to 40-year-old patients were included if they had experienced an invasive infection with encapsulated bacteria commonly encountered in PIDs (Streptococcus pneumoniae (SP), Neisseria meningitidis (NM), Neisseria gonorrhoeae (NG), Haemophilus influenzae (HI), or group A Streptococcus (GAS)). They were excluded in case of general or local predisposing factors. Immunological explorations and PIDs diagnoses were retrieved from medical records. Serum complement and IgG/A/M testings were systematically proposed at the time of study to patients with previously incomplete PID screening. RESULTS: The study population comprised 38 patients. Thirty-six had experienced a first invasive episode and a PID was diagnosed in seven (19%): two cases of common variable immunodeficiency revealed by SP bacteraemia, one case of idiopathic primary hypogammaglobulinaemia, and two cases of complement (C6 and C7) deficiency revealed by NM meningitis, one case of IgG2/IgG4 subclasses deficiency revealed by GAS bacteraemia, and one case of specific polysaccharide antibody deficiency revealed by HI meningitis. Two patients had previously experienced an invasive infection before the study period: in both cases, a complement deficiency was diagnosed after a second NM meningitis and a second NG bacteraemia, respectively. CONCLUSION: PID screening should be considered after a first unexplained invasive encapsulated-bacterial infection in young adults.


Asunto(s)
Bacteriemia/etiología , Bacteriemia/inmunología , Proteínas del Sistema Complemento/deficiencia , Síndromes de Inmunodeficiencia/complicaciones , Síndromes de Inmunodeficiencia/diagnóstico , Meningitis Bacterianas/etiología , Meningitis Bacterianas/inmunología , Adolescente , Adulto , Femenino , Humanos , Factores Inmunológicos/deficiencia , Masculino , Tamizaje Masivo/métodos , Prevalencia , Estudios Retrospectivos , Adulto Joven
15.
Clin Chim Acta ; 465: 123-130, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-28040558

RESUMEN

The complement system is an ancient and evolutionary conserved element of the innate immune mechanism. It comprises of more than 20 serum proteins most of which are synthesized in the liver. These proteins are synthesized as inactive precursor proteins which are activated by appropriate stimuli. The activated forms of these proteins act as proteases and cleave other components successively in amplification pathways leading to exponential generation of final effectors. Three major pathways of complement pathways have been described, namely the classical, alternative and lectin pathways which are activated by different stimuli. However, all the 3 pathways converge on Complement C3. Cleavage of C3 and C5 successively leads to the production of the membrane attack complex which is final common effector. Excessive and uncontrolled activation of the complement has been implicated in the host of autoimmune diseases. But the complement has also been bemusedly described as the proverbial "double edged sword". On one hand, complement is the final effector of tissue injury in autoimmune diseases and on the other, deficiencies of some components of the complement can result in autoimmune diseases. Currently available tools such as enzyme based immunoassays for functional assessment of complement pathways, flow cytometry, next generation sequencing and proteomics-based approaches provide an exciting opportunity to study this ancient yet mysterious element of innate immunity.


Asunto(s)
Enfermedades Autoinmunes/inmunología , Proteínas del Sistema Complemento/análisis , Proteínas del Sistema Complemento/inmunología , Enfermedades Autoinmunes/genética , Activación de Complemento , Proteínas del Sistema Complemento/deficiencia , Humanos , Inmunidad Innata , Lectina de Unión a Manosa/deficiencia , Lectina de Unión a Manosa/genética
17.
FP Essent ; 450: 35-53, 2016 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27869441

RESUMEN

There are 264 primary immunodeficiencies (PIDs), most of which are rare. They are caused by complement deficiencies, defects in phagocyte function, impaired T-cell function, and/or impaired B-cell function with antibody deficiencies. Most patients with PIDs will present, at varying ages, with frequent infections. These infections can be common respiratory tract infections such as otitis media or pneumonia, or they can be unusual bacterial, fungal, or parasitic infections. Neonatal screening for severe combined immunodeficiency syndrome, one of the most common and serious PIDs, is now performed in most US states, but many PIDs manifest and are detected after birth. Clinicians should be alert for PIDs when patients have unusual or frequent infection and perform a diagnostic evaluation. After ruling out HIV and hepatitis C infection, the next step is to obtain a complete blood count, immunodeficiency panel, and immunoglobulin and complement levels. If results are abnormal, or if a PID is suspected clinically but the diagnosis is not clear, prompt referral to an appropriate subspecialist is indicated. Some PIDs can be managed with stem cell transplantation, and transplantation before the first serious infection is associated with better outcomes. In addition, antimicrobial prophylaxis is indicated for many PIDs patients to prevent opportunistic infections.


Asunto(s)
Síndromes de Inmunodeficiencia/fisiopatología , Anomalías Múltiples/fisiopatología , Factores de Edad , Profilaxis Antibiótica/métodos , Linfocitos B/inmunología , Enfermedades Transmisibles/epidemiología , Proteínas del Sistema Complemento/deficiencia , Medicina Familiar y Comunitaria , Enfermedades Genéticas Congénitas/fisiopatología , Humanos , Síndromes de Inmunodeficiencia/diagnóstico , Síndromes de Inmunodeficiencia/epidemiología , Recién Nacido , Tamizaje Neonatal/métodos , Linfocitos T/inmunología , Vacunación
18.
Adv Clin Chem ; 77: 1-75, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27717414

RESUMEN

Historically, complement disorders have been attributed to immunodeficiency associated with severe or frequent infection. More recently, however, complement has been recognized for its role in inflammation, autoimmune disorders, and vision loss. This paradigm shift requires a fundamental change in how complement testing is performed and interpreted. Here, we provide an overview of the complement pathways and summarize recent literature related to hereditary and acquired angioedema, infectious diseases, autoimmunity, and age-related macular degeneration. The impact of complement dysregulation in atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, and C3 glomerulopathies is also described. The advent of therapeutics such as eculizumab and other complement inhibitors has driven the need to more fully understand complement to facilitate diagnosis and monitoring. In this report, we review analytical methods and discuss challenges for the clinical laboratory in measuring this complex biochemical system.


Asunto(s)
Proteínas del Sistema Complemento/análisis , Complemento C5/antagonistas & inhibidores , Proteínas del Sistema Complemento/deficiencia , Proteínas del Sistema Complemento/fisiología , Humanos
19.
Medicine (Baltimore) ; 95(37): e4871, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27631255

RESUMEN

A relationship between antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and complement has been shown, and complement has an important role in the pathogenesis of AAV. The clinical characteristics of AAV with hypocomplementemia still remain unclear.We conducted an observational study of 81 patients with AAV (median onset age 71 years; 58% female). Using medical records, we analyzed the patients' baseline variables, laboratory data, clinical symptoms, and therapeutic outcomes after treatments including episodes of relapses, initiation of dialysis, and death. We defined hypocomplementemia as the state in which at least one of the following was lower than the lower limit of the normal range: complement 3 (C3), complement 4 (C4), and total complement activity (CH50).Sixteen patients (20%) had hypocomplementemia at their diagnosis of AAV. Compared to the AAV patients without hypocomplementemia (n = 65), those with hypocomplementemia had significantly higher rates of the occurrence of skin lesions (8 [50%] vs. 8 [12%], P = 0.002), diffuse alveolar hemorrhage (DAH) (6 [38%] vs. 5 [8%], P = 0.006), and thrombotic microangiopathy (TMA) (3 [19%] vs. 0 [0%], P = 0.007). The AAV patients with hypocomplementemia had significantly lower platelet levels (16.5 × 10 vs. 24.9 × 10 cells/µL, P = 0.023) compared to those without hypocomplementemia. More positive immune complex deposits in renal biopsy specimens were seen in the AAV patients with hypocomplementemia than in those without hypocomplementemia (4 [80%] vs. 2 [18%], P = 0.036). Assessed by a log-rank test, hypocomplementemia at disease onset was significantly associated with death (P = 0.033).Hypocomplementemia in AAV at the disease onset was a risk factor for the serious organ damage, and a life prognostic factor. It is thus very important to pay attention to the levels of complement at the diagnosis of AAV.


Asunto(s)
Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/complicaciones , Proteínas del Sistema Complemento/deficiencia , Anciano , Antiinflamatorios/uso terapéutico , Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/sangre , Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/tratamiento farmacológico , Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/mortalidad , Femenino , Humanos , Japón/epidemiología , Masculino , Persona de Mediana Edad , Prednisolona/uso terapéutico , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...